Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG TEMPO PEN versus NOVOLOG MIX 70 30 FLEXPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG TEMPO PEN versus NOVOLOG MIX 70 30 FLEXPEN.
HUMALOG TEMPO PEN vs NOVOLOG MIX 70/30 FLEXPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially in skeletal muscle and fat, and by inhibiting hepatic glucose production. It binds to the insulin receptor, activating tyrosine kinase and downstream signaling pathways.
Insulin aspart is a rapid-acting insulin analog that lowers blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. It replaces endogenous insulin and has a faster onset and shorter duration than regular human insulin due to altered amino acid sequence (substitution of proline at position 28 with aspartic acid).
Subcutaneously, 0.2-0.5 units/kg within 15 minutes before or after a meal. Total daily dose is 0.5-1.0 units/kg.
Subcutaneous injection only. Initial total daily insulin dose: 0.5 to 1 unit/kg/day. Administer 70% intermediate-acting insulin aspart protamine and 30% rapid-acting insulin aspart. Typically given twice daily within 15 minutes before meals. Dose individualize based on glycemic goals.
None Documented
None Documented
1.0 hour (terminal elimination half-life); reflects rapid clearance of insulin lispro from circulation.
0.5-1 hour for the rapid-acting insulin aspart component and 8-10 hours for the protamine-crystallized insulin aspart component. Clinical context: biphasic profile allows for both prandial and basal coverage.
Renal: 100% of absorbed dose is eliminated via degradation, primarily in the liver and kidneys; no significant biliary/fecal excretion.
Renal elimination of degradation products. Approximately 30-40% of insulin dose is excreted unchanged in urine; the remainder is metabolized primarily in liver and kidney and excreted as metabolites.
Category C
Category C
Insulin Analog
Insulin Analog